

Doc code :IDS

PTO/SB/08a (03-08)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10000439
	Filing Date		2001-10-24
	First Named Inventor	Andrew Saxon	
	Art Unit	1644	
	Examiner Name	Huynh, Phuong N.	
	Attorney Docket Number	UCR-0674 US	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/PH/	1	7265208		2007-09-04	Saxon, et al.	
/PH/	2	5973121		1999-10-26	Burks Jr., et al.	
/PH/	3	4902495		1990-02-20	Kaliner, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/PH/	1	WO 96/22024	WO		1996-07-25	Brigham and Women's Hospital, Inc.	<input type="checkbox"/>

/Phuong Huynh/

09/02/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10000439
Filing Date		2001-10-24
First Named Inventor	Andrew Saxon	
Art Unit	1644	
Examiner Name	Huynh, Phuong N.	
Attorney Docket Number	UCR-0674 US	

/PH/	2	WO 99/57241	WO		1999-11-11	Corixa Corporation	<input type="checkbox"/>
/PH/	3	WO 96/16086	WO		1996-05-30	Neurocrine Biosciences, Inc.	<input type="checkbox"/>
/PH/	4	WO 02/102320	WO		2002-12-27	Tanox, Inc.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/PH/	1	Borel and Borel, A novel technique to link either proteins or peptides to gammaglobulin to construct tolerogens, J Immunol Methods. 1990 Feb 9;126(2):159-68.	<input type="checkbox"/>
/PH/	2	Borel and Borel, Oligonucleotide linked to human gammaglobulin specifically diminishes anti-DNA antibody formation in cultured lymphoid cells from patients with systemic lupus erythematosus J Clin Invest. 1988 Dec;82(6):1901-7.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Phuong Huynh/	Date Considered	09/02/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

COPY

SHEET 1 OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
	APPLICANT Saxon	
	FILING DATE October 24, 2001	GROUP Not yet assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1.	Bielekova, B. et al., "Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand," <u>Nature Medicine</u> , Vol. 6, No. 10, pp. 1167-1175 (2000).
	2.	Bridges, Jr., S. L. et al., "T-Cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis," <u>Emerging Therapies for Rheumatoid Arthritis</u> , Vol. 24, No. 3, pp. 641-650 (1998).
	3.	Chaillous, L. et al., "Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the M, 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM," <u>Diabetologia</u> , Vol. 37, pp. 491-499 (1994).
	4.	Delespesse, G. et al., "The Low-Affinity Receptor for IgE," <u>Immunological Reviews</u> , No. 125, pp. 77-97 (1992).
	5.	Dombrowicz, D. et al., "Anaphylaxis Mediated Through a Humanized High Affinity IgE Receptor," <u>The Journal of Immunology</u> , Vol. 157, pp. 1645-1651 (1996).
	6.	Gold, D. P. et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease," <u>Critical Reviews in Immunology</u> , Vol. 17, pp. 507-510 (1997).
	7.	Kaplan, "Urticaria and Angioedema," <u>Inflammation: Basic Principles and Clinical Correlates</u> , (Gallin and Snyderman Eds.), Chapter 35: 667-678 Raven Press, NY (1988).
	8.	Kappos et al., "Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial," <u>Nature Medicine</u> , Vol. 6, No. 10, pp. 1176-1182 (2000).
	9.	Kisselev, A. F. et al., "Proteasome Active Sites Allosterically Regulate Each Other, Suggesting a Cyclical Bite-Chew Mechanism for Protein Breakdown," <u>Molecular Cell</u> , Vol. 4, pp. 395-402 (1999).
	10.	McFarland, H. F., "Complexities in the Treatment of Autoimmune Disease," <u>Science</u> , Vol. 274, pp. 2037-2038 (1996).

EXAMINER	/Phuong Huynh/	DATE CONSIDERED	09/03/2008
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PH/

COPY

SHEET 2 OF 2

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UC067,004A	APPLICATION NO. 10/000,439
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Saxon	
		FILING DATE October 24, 2001	GROUP Not yet assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	11. Moreland, L. W. et al., "V β 17 T Cell Receptor Peptide Vaccination in Rheumatoid Arthritis: Results of Phase I Dose Escalation Study," <u>The Journal of Rheumatology</u> , pp. 1353-1362 (1996).
	12. Nepom, G. T., "Glutamic acid decarboxylase and other autoantigens," <u>Current Opinion in Immunology</u> , Vol. 7, pp. 825-830 (1995).
	13. Pamer, E. et al., "Mechanisms of MHC Class I-Restricted Antigen Processing," <u>Annu. Rev. Immunol.</u> , Vol. 16, pp. 323-358 (1998).
	14. Phillips, N. E. et al., "Cross-Linking of B Lymphocyte Fc γ Receptors and Membrane Immunoglobulin Inhibits Anti-Immunoglobulin-Induced Blastogenesis," <u>The Journal of Immunology</u> , Vol. 132, No. 2, pp. 627-632 (1984).
	15. Spack, E. G. et al., "Induction of Tolerance in Experimental Autoimmune Myasthenia Gravis with Solubilized MHC Class II:Acetylcholine Receptor Peptide Complexes," <u>Journal of Autoimmunity</u> , Vol. 8, pp. 787-807 (1995).
	16. TePas, E. C. et al., "Immunotherapy of asthma and allergic diseases," <u>Current Opinion in Pediatrics</u> , Vol. 12, pp. 574-578 (2000).
	17. Tunon, J. M., "Immunoglobulines E et cellules de l'inflammation," <u>Rev. Mal. Resp.</u> , Vol. 13, pp. 27-36 (1996).
	18. Weiner, H. L., <u>Science</u> , 259(5099):1321-1324 (1993).
	19. Yodoi, J. et al., "Low affinity IgE receptors: regulation and functional roles in cell activation," <u>1989 IgE, Mast Cells and the Allergic Response. Wiley, Chichester (Ciba Foundation Symposium 147) pp. 133-153.</u>
	20. Yoon, Ji-Won et al., "Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in β Cells," <u>Science</u> , Vol. 284, pp. 1183-1187 (1999).

W:\DOCS\IEJD\IED-1060.DOC\031902

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PH/

EXAMINER	/Phuong Huynh/	DATE CONSIDERED	09/03/2008
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			